Acquisition leverage Recent acquisition by TD2 International signals expanded capabilities and access to larger preclinical and clinical services networks. Use this to position Flow Contract Site Laboratory as a gateway for TD2’s customers seeking specialized flow cytometry CRO support within an integrated service suite.

Small biotech advantage With a lean team and specialized GLP and non-GLP flow cytometry services, FCSL presents a focused partner for startups and small-to-mid biotech firms that need expert immunophenotyping, receptor occupancy, and intracellular signaling assays without the overhead of a larger CRO.

Clinical and preclinical fit Capabilities spanning whole blood, tissue, frozen PBMCs and tumors for preclinical models and human trials create cross-sell opportunities into early-phase drug development programs requiring robust flow cytometry panels and cytokine detection.

Dimension expansion Multi-color (up to 8-color) flow cytometry and bead-based cytokine assays position FCSL to support complex immunology studies, enabling upsell into broader inflammatory and oncology research projects across TD2’s expanded platform.

Tech and data readiness Existing technology stack and Google Cloud infrastructure, along with website and lead tools, provide a practical entry point for partner-driven marketing, pilot projects, and scalable data management collaborations to accelerate client onboarding.